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Abstract Multiple system atrophy (MSA) is a rapidly pro-
gressive neurodegenerative disease. Post-mortem hallmarks
of MSA neuropathology include oligodendrogliala-synuclein
(aSYN) inclusions, striatonigral degeneration, olivoponto-
cerebellar atrophy, and increased microglial activation that
accompanies the wide spread neurodegeneration. Recently,
we demonstrated upregulation of myeloperoxidase (MPO) in
activated microglia and provided evidence for the role of
microglial MPO in the mediation of MSA-like neurodegen-
eration (Stefanova et al. Neurotox Res 21:393–404, 2015).
The aim of the current study was to assess the therapeutic
potency of MPO inhibition (MPOi) in a model of advanced
MSA. We replicated the advanced pathology of MSA by
intoxicating transgenic PLP-a-synuclein transgenic mice with
3-nitropropionic acid (3NP). After onset of the full-blown
pathology, MSA mice received either MPOi or vehicle over
3 weeks. Motor phenotype and neuropathology were ana-
lyzed to assess the therapeutic efficacy of MPOi compared to
vehicle treatment in MSA mice. MPOi therapy initiated after
the onset of severe MSA-like neuropathology in mice failed to
attenuate motor impairments and neuronal loss within the
striatum, substantia nigra pars compacta, inferior olives,
pontine nuclei, and cerebellar cortex. However, we observed a
significant reduction of microglial activation in degenerating
brain areas. Further, nitrated aSYN accumulation was
reduced in the striatonigral region. In summary, delayed-start
MPOi treatment reduced microglial activation and levels of
nitrated aSYN in a mouse model of advanced MSA. These
effects failed to impact on motor impairments and neuronal
loss in contrast to previously reported disease modifying
efficacy of early-start therapy with MPOi in MSA.
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Introduction
Multiple system atrophy (MSA) is a neurodegenerative
disease characterized by progressive autonomic failure,
cerebellar ataxia, and parkinsonism due to neuronal loss in
respective brain areas (Stefanova et al. 2009; Fanciulli and
Wenning 2015). Compared to idiopathic Parkinson’s dis-
ease (PD), it progresses more rapidly due to failure of
levodopa benefit (Krismer et al. 2014). Mean survival is
8–10 years after symptom onset, and sudden nocturnal
death is among the most frequent causes of death (Schrag
et al. 2008; Shimohata et al. 2008). Currently, therapeutic
interventions for MSA are limited (Kuzdas-Wood et al.
2014; Fanciulli and Wenning 2015). The lack of treatment
options aiming to modify the underlying pathophysiology
and the rapid deterioration of disease determine a major
need for developing disease modification strategies.
To date, the underlying pathomechanisms of MSA are
poorly understood, but the core feature of MSA pathology,
i.e., abundant aggregates of a-synuclein (aSYN) within
oligodendrocytes—also referred to as glial cytoplasmic
inclusions (GCIs)—led to the idea that MSA is a primary
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oligodendrogliopathy linked to ectopic aSYN accumula-
tion (Wenning et al. 2008; Song et al. 2007). The origin of
aSYN in GCIs is not completely understood. Current data
suggest oligodendroglial expression of the protein (Asi
et al. 2014), but propagation of neuronally derived aSYN
(Watts et al. 2013) may also play a role in the disease
cascade of MSA. Posttranslational modifications of aSYN
like hyperphosphorylation and nitration seem to associate
with the abnormal inclusion formation in MSA (Duda et al.
2000; Giasson et al. 2000; Kahle et al. 2002; Fujiwara et al.
2002). GCI pathology has been associated with neurode-
generation in the nigrostriatal and olivopontocerebellar
systems as well as linked to prominent microglial activa-
tion in MSA brains (Ozawa et al. 2004; Ishizawa et al.
2004).
Microgliosis and neuroinflammatory responses seem to
be an important contributor to the progression of neu-
rodegeneration in MSA; however, their roles in early stages
of the disease are difficult to assess in patients. In vivo
imaging demonstrates subcortical and brainstem microglial
activation in the brains of MSA patients (Gerhard et al.
2003). Post-mortem analyses show constituent presence of
activated microglia in MSA (Ishizawa et al. 2004, 2008;
Salvesen et al. 2015). Furthermore, several signaling
molecules associated with activated microglia including
toll-like receptor 4 (TLR4) upregulation, NFjB nuclear
translocation (Stefanova et al. 2007), and myeloperoxidase
(MPO) upregulation (Stefanova et al. 2012) have been
suggested to contribute to the pathogenesis of MSA and
have been further addressed in experimental models.
Therefore, preclinical models are instrumental to address
downstream pathogenic mechanisms linked to oligoden-
droglial aSYN accumulation.
To model MSA, transgenic mice were generated by
overexpression of human aSYN under the control of
specific oligodendroglial promoters, e.g., the myelin basic
protein promoter (Shults et al. 2005) or the proteolipid
protein (PLP) promoter (Kahle et al. 2002) resulting in the
formation of GCIs composed of insoluble, serine-129
hyperphosphorylated aSYN, resembling the hallmark
pathology of the human disease. The PLP-aSYN mouse
showed progressive but mild neuronal loss in substantia
nigra pars compacta (SNc) and specific brainstem nuclei
accompanied by microglial activation that might at least
partly mediate the neuronal loss (Stefanova et al. 2005,
2007; Stemberger et al. 2010; Boudes et al. 2013; Kuzdas
et al. 2013). Furthermore, PLP-aSYN mice showed
increased vulnerability to oxidative stress triggered by
3-nitropropionic acid (3NP) (Stefanova et al. 2005). While
both GCI-like pathology and oxidative stress alone may
trigger striatonigral degeneration (SND) and both factors
together result in an aggravated SND phenotype, olivo-
pontocerebellar atrophy (OPCA) can only be initiated
when both GCI-like pathology and mitochondrial dys-
function triggered by 3NP are present in the mouse brain
(Stefanova et al. 2005, 2014). This feature of the combined
PLP-aSYN ? 3NP mouse model (further designated as
MSA mouse model) makes it unique as a preclinical test-
bed of advanced MSA and provides the opportunity to test
therapeutic interventions in a setting of widespread selec-
tive neurodegeneration representing both SND and OPCA,
accompanied by GCIs and microglial activation.
Recently, we identified that MPO inhibition (MPOi) in
the PLP-a-SYN mouse can suppress microglial activation
and further mitigate in a dose-dependent manner the neu-
ronal loss induced by mitochondrial dysfunction through
3NP (Stefanova et al. 2012). Our primary conclusion was
that MPOi is an efficient neuroprotective strategy when
applied in the early non-symptomatic stages of MSA where
mild SND linked to GCI pathology precedes the aggrava-
tion of SND and the onset of OPCA triggered by 3NP. The
aim of the current study was to define whether the approach
of MPOi in MSA might hold promise as a neuroprotective
strategy even after the onset of SND and OPCA, i.e., in a
more advanced stage of the disease. We hypothesized that
MPOi might reduce the level of microglial activation and
post-translationally modified aSYN; however, behavioral
impairments and neuronal loss may be more resistant to a
delayed-start delivery in advanced MSA. For this purpose,
MPO inhibition with AZD3241 or vehicle treatment was
started after the induction of mitochondrial dysfunction by
3NP intoxication in PLP-aSYN mice.
Materials and Methods
Animals and Treatment
Homozygous transgenic PLP-aSYN mice overexpressing
human aSYN under the PLP-promotor as previously
characterized by Kahle and colleagues were used in this
study (Kahle et al. 2002). Animals were aged 8–9 months
at the beginning of the study. They were bred and housed
in a temperature-controlled room under a 12/12 h
(h) dark/light cycle with free access to food and water in
the animal facility of the Medical University of Innsbruck
under special pathogen-free conditions. During the study,
observation of animal health was performed on a daily
basis and all efforts were made to minimize the number of
animals used and their suffering. All experiments were
performed in accordance with the Austrian law and after
permission for animal experiments by the Federal Ministry
for Science and Research of Austria.
Transgenic male PLP-aSYN mice received 3NP intox-
ication according to a previously established dose
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escalation scheme as follows: 4 9 10, 4 9 20, 4 9 40,
4 9 50 mg/kg of 3NP, each dose applied four times
intraperitoneally in a 12 h rhythm. Treatment with either
AZD3241 (180 lmol/kg, n = 15) or vehicle (0.1 M meg-
lumine with 20 % w/v HPbCD, n = 15) was commenced
1 day after the last 3NP administration and was delivered
by oral gavage twice daily for 20 consecutive days in a
volume of 10 ml/kg body weight. AZD3241 doses and
target concentrations were chosen based on previous evi-
dence (Stefanova et al. 2012; Tiden et al. 2011).
Behavioral Analysis
The standardized clinical motor scale (CMS) was applied
daily during the total in vivo experiment to control the
efficacy of the 3NP intoxication as previously described
(Fernagut et al. 2002). Evaluation was performed every
morning prior to treatment throughout the study. The daily
scores ranged from 0 for a healthy animal to 10 for a
severely impaired mouse. For the group comparison, a
mean daily score per group over the experimental time was
calculated.
In addition, motor behavior was assessed at the end of
the treatment period by stride length test and open field
activity test as previously described (Stefanova et al. 2012)
with the investigator blinded to the treatment status of the
animals. For the stride length measurement, the hindlimbs
of mice were wetted with nontoxic food color. The mice
were let to run on a strip of paper (length: 42 cm, width:
4.5 cm) down a bright corridor to a dark enclosure. The
runs for each mouse were repeated four times. Finally, the
distance between consecutive steps of the left and right
hindlimb was measured and a mean stride length for each
mouse was determined. The initial (acceleration) and final
(deceleration) 7 cm of the runs were excluded from the
analysis.
The spontaneous cage activity, including the horizontal
and vertical (rearing) movements, was recorded for a per-
iod of 15 min applying the FlexField activity system (San
Diego Instruments, CA). The test sessions were performed
in the evening in a dark noise-isolated room.
Tissue Processing and Histological Analyses
Twenty-nine days after the start of the study, animals were
sacrificed via intraperitoneal application of thiopental
overdose (120 mg/kg b.w.) followed by transcardial per-
fusion using 4 % paraformaldehyde (PFA; pH 7.4). Sub-
sequently, brains were quickly removed and post-fixed
overnight in 4 % PFA at 4 C. Cryoprotection was per-
formed in a solution of 20 % sucrose in 0.01 M PBS pH
7.4 for at least 24 h. The brains were slowly frozen in
2-methylbutane at -40 C and stored at -80 C until
further processing. Serial sections of 40 lm were cut on a
cryostat (Leica, Nussloch, Germany). One full series was
stained with cresyl violet (CV), according to a standard
protocol. Monoclonal mouse anti-dopamine- and cAMP-
regulated neuronal phosphoprotein (anti-DARPP32, BD
Transduction Laboratories) was used to visualize and
quantify medium-sized spiny neurons of the striatum.
Monoclonal anti-tyrosine hydroxylase antibody (anti-TH,
Sigma, St. Louis, Missouri) was applied to visualize and
quantify nigral dopaminergic neurons. Monoclonal rat anti-
mouse CD11b was used to visualize activated microglia
cells (anti-CD11b, Serotec, Oxford, UK). Nitrated aSYN
antibody (Invitrogen, Camarillo, CA) was used to visualize
GCI-like inclusions. Secondary antibodies were biotiny-
lated anti-mouse, or anti-rat IgG (Vector, Burlingame, CA)
as appropriate. Visualization of the immunoproduct was
carried out with the ABC-kit (Vectastain ABC-kit, Vector
Laboratories, CA) and 3,30-diaminobenzidine (DAB).
Image Analysis
An observer blinded to the identity of the animals per-
formed all stereological investigations. The optical frac-
tionator was applied for cell number estimations in the
striatum, SNc, pontine nuclei, and inferior olives using a
computer-assisted image analysis system (Nikon E-800
microscope, Nikon digital camera DXM 1200; Stereo
Investigator Software, MicroBrightField Europe e.K.,
Magdeburg, Germany). Purkinje cells were counted in a
region outlined to include only the Purkinje cell layer
(Stefanova et al. 2012). Microglial activation was mea-
sured by determining mean gray values of CD11b
immunoreactivity in a region of interest (ROI). Back-
ground (BG) gray values were measured in the same
optical field out of the section. The relative optical density
(ROD) was obtained after a transformation of mean gray
values by using the formula ROD = -log (mean gray
ROI/mean gray BG). The density of nitrated aSYN inclu-
sions was measured in selected brain regions by delineating
the region and defining the area and the number of inclu-
sions within. Finally, GCI density was expressed as number
per mm2.
Statistics
Statistical comparisons were performed with GraphPad
Prism Version 5.03 using t test analysis to compare vehi-
cle- and MPOi-treated groups. Repeated measures
ANOVA was used to compare the progression of CMS in
the vehicle- and MPOi-treated group over the period of
4 weeks. Correlations between functional measures and
neuropathological readouts were done by linear regression
analysis. Data in graphs are presented as mean ± standard
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Daily evaluation of CMS following 3NP intoxication
showed progressive impairment in all animals within the
first 8 days of the experiment followed by a period of
disability over the next 3 weeks (effect of time:
F(3,1) = 143; p\ 0.001). After day 9, when the drug
treatment was initiated, the disability showed similar
severity and temporal evolution in both MPOi and vehicle-
treated MSA mice (effect of treatment: F(1,3) = 2.05;
p[ 0.05). After 20 consecutive days of treatment with
MPOi, no significant treatment effect associated with
MPOi therapy could be detected (Fig. 1a, b). A similar lack
of effect of MPOi on motor performance as determined by
stride length (Fig. 1c) and open field activity (Fig. 1d, e)
was evident at the end of the treatment period.
Fig. 1 a The daily clinical
motor score served to evaluate
the time course of the motor
impairment induced by 3NP
treatment (day 1–day 8) and its
course over the treatment period
with AZD3241 or vehicle (day
9–day 30). b Mean clinical
motor score per group over the
total experimental time
indicated lack of effect of
AZD3241 treatment (MPOi) on
the general motor disability in
MSA mice. c Stride length was
not changed under MPOi
treatment of MSA mice
compared to vehicle-treated
ones. d, e Rearing and
horizontal open field activities
were not affected by the MPOi
treatment of MSA mice
compared to vehicle-treated
MSA mice. Data are presented
as mean ± SEM.
MSA ? vehicle group, n = 15,
MSA ? MPOi group, n = 14
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Neuropathology
To assess the efficacy of MPOi treatment in a model of
advanced MSA, we measured neuronal numbers in SNc,
striatum, pontine nuclei, inferior olives, and cerebellar cor-
tex (Purkinje cells). Neuronal numbers remained unaffected
by the MPOi treatment compared to vehicle in all studied
regions (Fig. 2). However, a strong biological effect of the
MPOI treatment was detected on microglial activation being
significantly reduced in SNc (p = 0.027), pontine nuclei
(p = 0.0018), inferior olives (p = 0.02), and corpus callo-
sum (p = 0.0056). There was significant correlation
between the levels of microglial activation and the number of
nigral neurons (R2 = 0.1686, p = 0.0334). Although there
was a numerical decrease in the ROD of microglial activa-
tion in the striatum after MPOi treatment (MSA ? vehicle,
0.14 ± 0.018 vs. MSA ? MPOi, 0.11 ± 0.012), the dif-
ference to vehicle-treated mice did not reach statistical sig-
nificance (p = 0.1632) (Fig. 3). Furthermore, the treatment
with MPOi resulted in significantly reduced density of
nitrated aSYN inclusions compared to vehicle-treated MSA
mice in SNc (p = 0.0022) and striatum (p = 0.016) but not
in the inferior olives (p = 0.47), pontine nuclei (p = 0.53),
or the cerebellar cortex (p = 0.55) (Fig. 4).
Fig. 2 DARPP32-positive medium spiny neurons of the striatum of
MSA ? vehicle (n = 9) (a) and MSA ? MPOi group (n = 7) (b).
There was no significant effect of AZD3241 treatment on the number
of striatal DARPP32 positive neurons in MSA mice (c). TH-positive
dopaminergic neurons in SNc of MSA ? vehicle (n = 14) (d) and
MSA ? MPOi group (n = 13) (e). MPOi treatment showed no
significant neuroprotective effect on nigral TH neurons in MSA mice
(f). Further, no neuroprotective efficacy of MPOi could be registered
in the inferior olives (nvehicle = 6, nMPOi = 6) (g), the pontine nuclei
(nvehicle = 5, nMPOi = 7) (h), and the Purkinje cells in the cerebellar
cortex (nvehicle = 6, nMPOi = 8) (i). Data are presented as
mean ± SEM
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Discussion
We provide preclinical evidence that MPO inhibition in a
model of advanced MSA suppresses microglial activation
without significant preservation of neurons in the stria-
tonigral or the olivopontocerebellar regions of the brain
and no significant behavioral changes compared to vehicle-
treated MSA mice. Furthermore, we report significant
reduction of nitrated aSYN-positive inclusions in SNc and
striatum but not in the olivopontocerebellar pathway,
suggesting that nitrated aSYN accumulation in the MSA
mouse brain is not exclusively determined by levels of
microglial activation. Finally, our findings suggest that the
reduction of microglial activation induced by MPOi (as
confirmed previously both preclinically (Stefanova et al.
2012) and in a clinical trial (Jucaite et al. 2014)) may
interfere with the degree of neuronal loss, and the degree of
GCI density and motor improvement; however, these
effects are significantly detectable only by early-start or
‘‘preventive’’ delivery of MPOi in a model of ‘‘early’’ MSA
(Stefanova et al. 2012) but masked in a delayed-start
paradigm applied to a model of ‘‘advanced’’ MSA.
Microglial activation is a prominent and consistent
feature of human MSA pathology (Ishizawa et al. 2004;
Gerhard et al. 2003; Salvesen et al. 2015) and its contri-
bution to the disease mechanisms is broadly discussed
(Fellner et al. 2011; Halliday and Stevens 2011; Sanchez-
Guajardo et al. 2015). At post-mortem examination,
microglial burden in the degenerating gray matter does not
correlate with the remaining neuronal counts (Ishizawa
et al. 2008); however, it is still unclear what the role of
microglial activation in earlier stages of the disease may be
and to what extent it contributes to the neurodegenerative
process. Experimental evidence suggests that microglial
activation in MSA models may have detrimental role
through the upregulation of iNOS and increased release of
nitric oxide in SNc in early stages of the disorder (Ste-
fanova et al. 2007). Alternatively subpopulation of acti-
vated microglial cells may be responsible for the clearance
of deleterious aSYN species through TLR4, thus having a
rescue effect for nigral neurons (Stefanova et al. 2011). The
current study together with our previous observations on
the role of MPOi in early MSA (Stefanova et al. 2012)
suggests that microglial activation can have different
degree of effect on neuronal loss in MSA, dependent on the
disease stage. When microglial activation is suppressed in
early stages of the disease through MPOi, significant neu-
roprotection can be observed (Stefanova et al. 2012).
Microglial suppression through the same dose and mode of
application of MPOi in an advanced stage of neuronal loss
in MSA mice is ineffective to protect the degenerating
neurons in the affected areas. The current observations
point toward the paramount importance of identifying an
optimal treatment window in relation to the time course of
neurodegeneration, which may explain the lack of efficacy
of the delayed-start MPOi treatment on neuronal loss and
motor function. However, we identified mild but significant
correlation between levels of microglial activation and
number of nigral neurons, supporting previously reported
neuroprotection linked to reduced microglial activation.
Furthermore, nitric oxide and superoxide released by
activated microglia have been previously proposed as
mediators that link neuroinflammation and abnormally
nitrated aSYN accumulation which may finally lead to
nigral neuronal loss (Gao et al. 2008). Our results here
support this conclusion indicating that suppression of
microglial activation by MPOi treatment indeed leads to
significant reduction of nitrated aSYN accumulation in
SNc and striatum as we showed also in a previous exper-
iment (Stefanova et al. 2012). However, no other of the
analyzed regions—inferior olives, pontine nuclei, and
cerebellar cortex—showed significant interrelations
between the level of microglial activation and the density
of nitrated aSYN inclusions suggesting region-specific
interactions between oxidative stress, microglial activation,
and aSYN pathology in a model of advanced MSA.
Region-specific vulnerability has been previously descri-
bed in PLP-aSYN mice. In this transgenic model, SNc and
striatum undergo progressive neurodegeneration induced
by GCI-like pathology (Stefanova et al. 2014) and this
pathology can be further aggravated by mitochondrial
dysfunction (3NP). On the contrary, the olivopontocere-
bellar region can be affected by neurodegeneration only in
the presence of both GCIs and mitochondrial dysfunction
bFig. 3 CD11b immunohistochemistry in striatum of a MSA ? vehi-
cle and b MSA ? MPOi (AZD3241) group. c Statistical analysis
indicated a tendency to reduction of the microglial activation in the
striatum without reaching significance (nvehicle = 14, nMPOi = 14).
CD11b immunohistochemistry in substantia nigra (SN) of
d MSA ? vehicle and e MSA ? MPOi group. f MPOi treatment of
MSA mice resulted in significant reduction of CD11b ROD in
substantia nigra (*p\ 0.05 compared to MSA ? vehicle; nvehi-
cle = 14, nMPOi = 14). CD11b immunohistochemistry in the pontine
nuclei of g MSA ? vehicle and h MSA ? MPOi group. i MPOi
treatment of MSA mice resulted in significant reduction of CD11b
ROD in the pontine nuclei of MSA mice receiving AZD3241
compared to vehicle-treated animals (**p\ 0.01; nvehicle = 12,
nMPOi = 12). CD11b immunohistochemistry in the inferior olives of
j MSA ? vehicle and k MSA ? MPOi group. l MPOi treatment of
MSA mice resulted in significant reduction of CD11b ROD in the
inferior olives of MSA mice receiving AZD3241 compared to
vehicle-treated animals (*p\ 0.05; nvehicle = 13, nMPOi = 14).
CD11b immunohistochemistry in the cerebellar cortex of
m MSA ? vehicle and n MSA ? MPOi group. o MPOi treatment
of MSA mice resulted in significant reduction of CD11b ROD in the
pontine nuclei of MSA mice receiving AZD3241 compared to
vehicle-treated animals (***p\ 0.001; nvehicle = 11, nMPOi = 11).
Data are presented as mean ± SEM
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(3NP) (Stefanova et al. 2005). This region-specific vul-
nerability is now further complemented by the observation
that the interaction between mitochondrial dysfunction and
GCIs can be modulated by microglial activation in the
striatonigral but not in the olivopontocerebellar region.
As mitochondrial dysfunction is a valid candidate
pathogenic mechanism in MSA as suggested by the finding
of Coq2 mutations in MSA families (The Multiple-System
Atrophy Research Collaboration 2013) and the central role
of aSYN in the pathogenesis of MSA is unequivocal, it
seems that the combined PLP-aSYN ? 3NP model pro-
vides a relevant tool to address these two factors, their
interplay and interaction with neuroinflammatory respon-
ses. It is likely that the subacute injury with 3NP in the
PLP-aSYN mouse differs from the slowly progressive
human MSA pathology which may relate to a better effi-
cacy of MPOi therapy in human MSA. Despite the limi-
tations of the mechanistic modeling approach that cannot
100 % reflect the dynamics of the human disease, we
believe that it provides important insights into the possible
scenarios of interaction between GCI pathology, mito-
chondrial dysfunction, and neuroinflammation and can give
relevant answers to their role in development of therapeutic
strategies for MSA.
Clinical Relevance
The current dataset provides an important follow-up on the
preclinical screening of MPOi and its therapeutic efficacy
dependent on the stage of treatment initiation in a model of
MSA. We reported previously that a preventive therapeutic
regimen of MPOi in MSA mice replicating human GCI-
like pathology prevented motor deterioration and conferred
neuroprotection in SNc, striatum, cerebellar cortex, pontine
nuclei, and inferior olives (Stefanova et al. 2012). The
neuroprotective effects of MPOi were associated with
reduction of microglial activation and diminished density
of GCIs in the affected brain areas. Despite the profound
beneficial behavioral and neuroprotective effects of MPOi
therapy when initiated in a presymptomatic phase of MSA,
our current results show that the effects of the therapy may
be limited when drug application is started in an advanced
symptomatic stage of the disease. Although we observed
reduced microglial activation correlating with mild nigral
neuronal preservation, this was not associated with signif-
icant motor improvement or reversal of SND and OPCA
pathology in a double-hit model of advanced MSA.
In line with our results and their clinical relevance, a
recent report on AZD3241 treatment in PD patients showed
reduced levels of [11C]PBR28 binding to dopamine trans-
porter and translocator protein in PET imaging indicating
suppressed microglia activity (Jucaite et al., 2014). Taken
together, the findings on MPOi therapy in the MSA mouse
model and the randomized controlled trial in PD patients
unequivocally point toward a strong biological effect of
MPOi in the CNS and indicate that early timing of delivery
is paramount in future MSA trials.
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